Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
The Lancet. Neurology|October 3, 2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trialScott E Kasner, Balakumar Swaminathan, Pablo Lavados, et al.Stroke|September 20, 2021
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS TrialMukul Sharma, Eric E Smith, Lesly A Pearce, et al.JAMA Neurology|October 19, 2020
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical TrialAshkan Shoamanesh, Robert G Hart, Stuart J Connolly, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|June 5, 2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS TrialRobert G Hart, Roland C Veltkamp, Patrick Sheridan, et al.JAMA Neurology|July 7, 2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical TrialRoland Veltkamp, Lesly A Pearce, Eleni Korompoki, et al.International Journal of Stroke : Official Journal of the International Stroke Society|November 18, 2021
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudyMukul Sharma, Eric E Smith, Lesly A Pearce, et al.Stroke|August 11, 2016
Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global RegistryKanjana S Perera, Thomas Vanassche, Jackie Bosch, et al.Lancet (London, England)|March 23, 2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trialE Magnus Ohman, Matthew T Roe, P Gabriel Steg, et al.JAMA Neurology|April 9, 2019
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical TrialJeff S Healey, David J Gladstone, Balakumar Swaminathan, et al.JAMA Cardiology|March 26, 2025
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical TrialJohn H Alexander, Elizabeth J Lydon, Jonathan P Piccini, et al.Pageof 5